A new study reveals experimental drug XL20 crosses the blood-brain barrier to stop toxic TDP-43 clumping in ALS.

Amyotrophic lateral sclerosis (ALS) received widespread attention in the summer of 2014 thanks to the Ice Bucket Challenge. Millions of people participated, drenching themselves in ice-cold water to ...

CNS metastases represent one of the most devastating complications of non-small-cell lung cancer (NSCLC), affecting up to 50% of patients during their ...

Axsome Therapeutics(NASDAQ: AXSM) has been going through a particularly significant growth phase in recent years, launching ...

Lowri Denman, a 42-year-old woman from the UK, experienced a shocking health incident in 2010 when she passed a meter-long ...

Researchers report encouraging early results from a first-in-human clinical trial led by Children's National using a new ...

Tsingke Biotech recently hosted the Oligonucleotide Drug Salon at the Hilton Shanghai Zhangjiang, bringing together experts ...

"A hallmark of ADHD is that even faint distractors draw attention away – and that's exactly what we see here when these ...

Plus Therapeutics to become Cerenome, to trade under new Nasdaq ticker CNSY on August 3, 2026Affirms 2026 guidance on key milestones Reports ...

Brain metastases are a major challenge in HER2-positive metastatic breast cancer; epidemiologic series suggest that roughly 30%–50% of patients eventually develop brain involvement, which is ...

Investment firm Deerfield Management is the latest to find a gem in China, which has been rising as a source of biotech innovation over the past few years. Investment firm Deerfield Management has ...